Mostrar el registro sencillo del ítem

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases

dc.contributor.authorRodríguez Padial, Luis
dc.contributor.authorBarón Esquivias, Gonzalo
dc.contributor.authorHernández-Madrid, Antonio
dc.contributor.authorMarzal Martín, Domingo
dc.contributor.authorPallarés-Carratalá, Vicente
dc.date.accessioned2017-06-28T16:04:04Z
dc.date.available2017-06-28T16:04:04Z
dc.date.issued2016
dc.identifier.citationPadial, L. R., Baron-Esquivias, G., Madrid, A. H., Martín, D. M., Pallares-Carratala, V., & Sierra, A. (2016). Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases. Cardiology and therapy, 5(1), 75-82ca_CA
dc.identifier.issn2193-8261
dc.identifier.issn2193-6544
dc.identifier.urihttp://hdl.handle.net/10234/168131
dc.description.abstractCardiovascular diseases are the leading cause of death in the world. Coronary artery diseases, atrial fibrillation or hypertensive heart disease, are among the most important cardiovascular disorders. Hypertension represents a significant risk factor for cardiovascular mortality; thus, control of high blood pressure has become a priority to prevent major complications. Although the choice of drugs for treating hypertension remains controversial, extensive clinical evidences point to calcium channel blockers as first-line agents. Diltiazem, a non-dihydropyridine calcium channel blocker, is an effective and safe antihypertensive drug, alone or in combination with other agents. Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility, representing also a good alternative for the treatment of stable chronic angina. Furthermore, diltiazem reduces conduction in atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. In this review, clinical experts highlight studies on diltiazem effectiveness and safety for the treatment of several cardiovascular diseases and make evidence-based recommendations regarding the management of diltiazem in the clinical pracca_CA
dc.description.sponsorShipSponsorship for this review and the article processing charges was funded by Lacer Spain. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Writing assistance in the preparation of this manuscript was provided by Patricia Rodriguez, PhD, and editorial assistance was provided by Springer Healthcare. Support for this assistance was funded by Lacer Spain.ca_CA
dc.format.extent8 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherSpringer Verlag (Germany)ca_CA
dc.relation.isPartOfCardiology and therapy, 2016, vol. 5, núm. 1ca_CA
dc.relation.isPartOfAn erratum to this article can be found at http://dx.doi.org/10.1007/s40119-016-0062-6.
dc.rights© The Author(s) 2016. This article is published with open access at Springerlink.com This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.ca_CA
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAnginaca_CA
dc.subjectAtrial arrhythmiaca_CA
dc.subjectCalcium channel blocker (CCB)ca_CA
dc.subjectDiltiazemca_CA
dc.subjectHypertensionca_CA
dc.titleClinical Experience with Diltiazem in the Treatment of Cardiovascular Diseasesca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/ 10.1007/s40119-016-0059-1
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://link.springer.com/article/10.1007/s40119-016-0059-1ca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersion


Ficheros en el ítem

Thumbnail
Nombre:
license_rdf
Tamaño:
1.337Kb
Formato:
application/rdf+xml
Ver/Abrir
Thumbnail
Nombre:
rodriguez_2016_Cli.pdf
Tamaño:
411.5Kb
Formato:
PDF
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© The Author(s) 2016. This article is published with open access at Springerlink.com This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Excepto si se señala otra cosa, la licencia del ítem se describe como: © The Author(s) 2016. This article is published with open access at Springerlink.com This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.